Affiliation:
1. Anhui Medical University
Abstract
Abstract
Background
To investigate the application value of plasma human cysteine protease inhibitor S (CST4) in the diagnosis of digestive system malignant tumors in our hospital.
Methods
Serum CST4, AFP, CEA, CA199, CA125, CA153 and CA724 were detected in 100 patients with digestive system malignant tumors and 100 patients with benign diseases.
Results
In the diagnosis of digestive system malignant tumors, the sensitivity of CST4 was higher than that of other indicators, and the specificity of CA153 and AFP was higher than that of other indicators. CST4 combined with AFP, CEA, CA199, CA125, CA153, and CA724 did not reduce the specificity, and the sensitivity, accuracy, and positive likelihood ratio of the detection were significantly improved.
Conclusions
The CST4 assay is a promising diagnostic tool. At the same time, combining the existing tumor markers with comprehensive judgment can improve the accuracy of the diagnosis of digestive system malignant tumors.
Publisher
Research Square Platform LLC
Reference42 articles.
1. Gonzalez RS, Raza A, Propst R et al. Recent Advances in Digestive Tract Tumors: Updates From the 5th Edition of the World Health Organization "Blue Book". Arch Pathol Lab Med. 2021 May 1;145(5):607–626.
2. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019;GBD 2019 Cancer Risk Factors Collaborators;Lancet
3. Global Burden of 5 Major Types of Gastrointestinal Cancer;Arnold M;Gastroenterology
4. Roles of fusion genes in digestive system cancers: Dawn for cancer precision therapy;Zhang Y;Crit Rev Oncol Hematol
5. Clinical value of serum AFP and PIVKA-II for diagnosis, treatment and prognosis of hepatocellular carcinoma;Tian S;J Clin Lab Anal